Our strategy is to focus  our expertise and strength on late preclinical development to early proof-of-concept clinical trials. By leveraging our core technology and development expertise and strategically partnering with and CRO/CDMO (Contract Research Organization/Contract and Development Manufacturing Organization) and well renowned academic institutions, we strive to build a dynamic business that fosters innovative, flexible and productive biotechnological enterprise.